NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient

Haematologica. 2018 Sep;103(9):e424-e426. doi: 10.3324/haematol.2017.186742. Epub 2018 Apr 27.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Biomarkers, Tumor
  • Biopsy
  • Bone Marrow / metabolism
  • Bone Marrow / pathology
  • Drug Resistance, Neoplasm
  • Humans
  • Immunohistochemistry
  • Immunotherapy, Adoptive* / methods
  • Leukemia, Myeloid, Acute / diagnosis
  • Leukemia, Myeloid, Acute / genetics
  • Leukemia, Myeloid, Acute / immunology*
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • NK Cell Lectin-Like Receptor Subfamily K / immunology*
  • NK Cell Lectin-Like Receptor Subfamily K / metabolism*
  • Receptors, Antigen, T-Cell / genetics
  • Receptors, Antigen, T-Cell / metabolism
  • Receptors, Chimeric Antigen / genetics
  • Receptors, Chimeric Antigen / metabolism*
  • Recurrence
  • Remission Induction
  • T-Lymphocytes / immunology
  • T-Lymphocytes / metabolism
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • KLRK1 protein, human
  • NK Cell Lectin-Like Receptor Subfamily K
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen